Home > Healthcare > Medical Devices > Diagnostic Devices > Cancer Diagnostics Market

Cancer Diagnostics Market Trends

Report ID: GMI2406
Published Date: Nov 2024
Report Format: PDF

Download Free Sample

Cancer Diagnostics Market Trends

Numerous initiatives by governments and health organizations to raise awareness about cancer and reduce the disease burden are expected to positively impact the growth of the market.
One notable campaign launched by the Pan American Health Organization (PAHO), St. Jude Children's Research Hospital, and Childhood Cancer International aims to educate parents, caregivers, and healthcare professionals in Latin America and the Caribbean about the early warning signs of the most common cancers in children and adolescents.
Additionally, February 15th is recognized as International Childhood Cancer Day to support children battling cancer. This observance seeks to enhance public awareness of prevalent pediatric cancers such as lymphoblastic leukemia, Hodgkin lymphoma, and retinoblastoma.

Authors: Mariam Faizullabhoy , Gauri Wani

Frequently Asked Questions (FAQ) :

The global cancer diagnostics industry was valued at approximately USD 158.7 billion in 2024 and is estimated to grow at a 9% CAGR from 2025 to 2034, driven by advancements in diagnostic technologies and increasing cancer prevalence.

The liver and lung cancer segment accounted for an 18.4% market share in 2024 and is projected to reach USD 65.5 billion by 2034, fueled by rising incidences of these cancers and advancements in diagnostic methods.

The U.S. cancer diagnostics market is projected to grow significantly, reaching USD 135 billion by 2034, driven by an aging population, lifestyle choices, and environmental exposures.

Key players in the industry include Abbott Laboratories, AB Sciex Pte, Agilent Technologies, Becton, Dickinson and Company, Biocare Medical, Biocartis, Biomerieux, Bio-Rad Laboratories, Danaher Corporation, F-Hoffmann-La Roche, and GE Healthcare.